| Reconciliation Of Operating Profit Loss From Segments To Consolidated |
For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
|
Nine months ended September 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
(in thousands) |
|
|
(in thousands) |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Personnel |
|
$ |
11,700 |
|
|
$ |
10,289 |
|
|
$ |
35,066 |
|
|
$ |
27,453 |
|
Clinical trials |
|
|
10,872 |
|
|
|
6,228 |
|
|
|
28,453 |
|
|
|
15,963 |
|
Development services |
|
|
3,677 |
|
|
|
4,495 |
|
|
|
11,442 |
|
|
|
12,954 |
|
Manufacturing |
|
|
12,997 |
|
|
|
4,835 |
|
|
|
29,639 |
|
|
|
12,176 |
|
License of intellectual property |
|
|
— |
|
|
|
4 |
|
|
|
— |
|
|
|
1,519 |
|
Other research and development costs (1) |
|
|
578 |
|
|
|
439 |
|
|
|
1,880 |
|
|
|
1,606 |
|
General and administration expenses |
|
|
6,764 |
|
|
|
6,756 |
|
|
|
23,150 |
|
|
|
19,685 |
|
Interest income |
|
|
(1,808 |
) |
|
|
(2,417 |
) |
|
|
(4,705 |
) |
|
|
(8,078 |
) |
Interest expense |
|
|
584 |
|
|
|
— |
|
|
|
1,449 |
|
|
|
— |
|
Other income, net |
|
|
(498 |
) |
|
|
— |
|
|
|
(437 |
) |
|
|
— |
|
Net loss |
|
$ |
44,866 |
|
|
$ |
30,629 |
|
|
$ |
125,937 |
|
|
$ |
83,278 |
|
(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.
|